Preview

Rational Pharmacotherapy in Cardiology

Advanced search

A Prospective, Initiative, Single-Center Open Post-Registration Comparative Study of Laboratory Efficacy of Various Forms of Acetylsalicylic Acid in a Cardioprotective Dose with Different Composition of Excipients: Results of the SFAIROS Study

https://doi.org/10.20996/1819-6446-2020-06-06

Full Text:

Abstract

Aim. To compare the kinetics of dissolution (in vitro) and some pharmacodynamic and pharmacokinetic parameters of branded generic preparations of acetylsalicylic acid (ASA) in buffered form in cardioprotective doses [ASA 75 mg+Mg(OH)2 15.2 mg], which differ in the composition of excipients, with a reference drug.

Material and methods. Patients with cardiovascular diseases who had indications for ASA monotherapy (n=75) were included in a one-center open postregistration comparative non-randomized study. Patients were divided into 3 groups for treatment with one of the three studied drugs: Cardiomagnyl® (comparison drug; group 1; n=25), Trombital® (group 2; n=25) and Fazostabil® (group 3; n=25). A study of the kinetics of dissolution of the studied drugs in vitro under conditions of pH 1.2 has been performed. Also, platelet aggregation in response to arachidonic acid, the concentration of salicylic acid and the level of serum thromboxane B2 were studied in the compared groups.

Results. The average release profile of ASA by the 30th minute from Cardiomagnyl® was higher than for Trombital® and Fazostabil® (95.7%, 84.8%, 76.5% respectively). The similarity factor (f2) of ASA release for Trombital® was 39.3, and for Fazostabil® - 34.2. An index of f2<50 indicates a nonequivalent release of ASA compared with the reference drug. The serum level of salicylic acid 2 hours after taking the first dose of the drug in patients of group 1 was 2657.3±648.4 ng/ml, in group 2 - 2637.0±740.0 ng/ml (p=0.03) and in group 3 it was to 2632.1±666.0 ng/ml (p=0.002). The platelet aggregation after 3 days decreased and in groups 1, 2 and 3 were respectively 7.6%, 32.2% (p=0.000) and 16.3% (p=0.009). Differences in the disaggregation effect between the groups persisted by the 7th day of the study (7.9%, 9.1% and 20.5% respectively; p=0.04 for the latter). The thromboxane B2 level by the 3rd day of administration decreased compared to the initial level in group 1 to 15.5%, in group 2 to 21.1% and in group 3 to 20.0% (p=0.05 for both). The trend persisted by the 7th day.

Conclusion. The pharmacodynamic and pharmacokinetic parameters of the studied drugs differed statistically significantly with the advantage for the comparison drug despite the same active substance.

About the Authors

N. V. Lomakin
Central Hospital with Outpatient Department, Administrative Department of the President of the Russian Federation
Russian Federation

Nikita V. Lomakin - MD, PhD, Head of Cardiac Resuscitation Department, Central Hospital with Outpatient Department, Administrative Department of the President of the Russian Federation.

Marshala Tymoshenko ul. 15, Moscow, 121359.



L. I. Buryachkovskaya
National Medical Research Center of Cardiology
Russian Federation

Lyudmila I. Buryachkovskaya - PhD (Biology), Leading Researcher, Institute of Experimental Cardiology, National Medical Research Center of Cardiology.

Tretya Cherepkovskaya ul. 15a, Moscow, 121552.



D. A. Zolin
Central Hospital with Outpatient Department, Administrative Department of the President of the Russian Federation
Russian Federation

Denis A. Zolin - MD, Doctor, Cardiac Resuscitation Department, Central Hospital with Outpatient Department, Administrative Department of the President of the Russian Federation.

Marshala Tymoshenko ul. 15, Moscow, 121359.



V. I. Kazey
LLC “EXAKTE LABS”
Russian Federation

Vasily I. Kazey - PhD (Biology), Director, LLC “EXAKTE LABS”.

Nauchnii pr. 20-2, Moscow, 117246.



References

1. Jain K.K. Investigation and management of loss of efficacy of an antiepileptic medication using carbamazepine as an example. J R Soc Med. 1993;86(3):133-6. PMCID: PMC1293899.

2. Privitera M.D. Generic Antiepileptic Drugs: Current Controversies and Future Directions. Epilepsy Currents. 2008;8(5):11-17. DOI:10.1111/j.1535-7511.2008.00261.x.

3. Ringe J.D., Moller G. Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysis. Rheumatol Int. 2009;30:213-21. DOI:10.1007/s00296-009-0940-5.

4. Kanis J.A., Reginster J., Kaufman J., et al. A reappraisal of generic bisphosphonates in osteoporosis. Osteoporos Int. 2012;23:213-21. DOI:10.1007/s00198-011-1796-6.

5. Diez-Perez A., Adachi J.D., Agnusdei D., et al. Treatment failure in osteoporosis. Osteoporos Int. 2012;23:2769-74. DOI:10.1007/s00198-012-2093-8.

6. De Vuono A., Scicchitano F., Palleria C., et al. Lack of efficacy during the switch from brand to generic allopurinol. J Forensic Leg Med. 2013;20:540-2. DOI:10.1016/j.jflm.2013.02.007.

7. De Vuono A., Palleria C., Scicchitano F., et al. Skin rash during treatment with generic itraconazole. J Pharmacol Pharmacother, 2014;5(2):1 58-160. doi:10,4103/0976-500X.130086.

8. Versantvoort C.H., Maliepaard M., Lekkerkerker F. Generics: what is the role of registration authorities. Neth J Med. 2008;66(2):62-66. PMID:18292608.

9. Committee for Medicinal Products for Human Use. Guideline on the investigation of bioequivalence. London: European Medicines Agency (2010) [cited by Feb 01, 2020]. Available from: http://www.ema.europa.eu/pdfs/human/qwp/140198enrev1fin.pdf.

10. Filho O., Melor E. Quality assessment of samples of generic and similar aspirin tablets (500 mg) marketed in Brazil. Rev Bras Farm. 2013;94(1):35-40.

11. Kiselev A.R., Akhobekov A.A., Schwartz V.A. Acetylsalicylic acid preparations in patients with cardiovascular diseases: important aspects of efficacy and safety. Russian Medical Journal. 2014;22(23):1670-2 (In Russ.).

12. Lomakin N.V., Rusanova A.V., Buryachkovskaya L.I., et al. Comparison of the antiplatelet efficacy of various forms of acetylsalicylic acid. Heart: A Journal for Practitioners. 2014;13(4):206-15 (In Russ.).

13. Buryachkovskaya L.I., Lomakin N.V., Rusanova A.V., Vershinina M.G. Resistance to acetylsalicylic acid: causes and effect. Heart: A Journal for Practitioners. 2016;15(5):379-88 (In Russ.). DOI:10.18087/rhj.2016.5.2261.

14. Bhatt D.L., Grosser T., Dong J.F., et al. Enteric coating and aspirin nonresponsiveness in patients with type 2 diabetes mellitus. JACC. 2017;69(6):603-12. DOI:10.1016/j.jacc.2016.11.050.

15. Grosser T., Fries S., Lawson J.A., et al. Drug resistance and pseudoresistance: an unintended consequence of enteric coating aspirin. Circulation. 2013;127(3):377-85. DOI:10.1161/CIRCULATION-AHA.112.117283.

16. Karha J., Rajagopal V., Kottke-Marchant K., et al. Lack of effect of enteric coating on aspirin-induced inhibition of platelet aggregation in healthy volunteers. Amer Heart J. 2006;151(5):976.e7-976.e11. DOI:10.1016/j.ahj.2006.02.017.

17. Leonards J.R., Levy G. Absorption and metabolism of aspirin administered in enteric-coated tablets. JAMA. 1965;193(2):99-104. DOI:10.1001/jama.1965.03090020013004.

18. Bland J.H. Absorption of Enteric-Coated Aspirin-Reply. JAMA. 1983;249(2):192-3. DOI:10.1001/jama.1983.03330260016012.

19. Roffi M., Patrono C., Collet J.P., et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(3):267-315. DOI:10.1093/eu-rheartj/ehv320.

20. Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use. Off J Eur Communities. 2001;L121:33-44.

21. Gohary O.M., Din K., Tahir H. Formulation of aspirin-magaldrate double-layer tablets: in vitro evaluation and cytoprotective activity in rats. Bollettino Chimicopharmaceutics. 1996;135(7):421-8. PMID:9035555.

22. Abe T., Yanagihara Y., Uchino T., et al. Evaluation of the pharmaceutical characteristics of various entericcoated aspirin tablets under different storage conditions. Chem Pharm Bull. 2014;62(7):617-26. DOI:10.1248/cpb.c13-00580.

23. Singh P., Kumar P., Prasad N. Formulation and evaluation of aspirin tablets by using different lubricants in combination for better kinetic drug release study by PCP. Research Journal of Pharmacy and Technology. 2017;10(9):2934-8. DOI:10.5958/0974-360X.2017.00519.4.

24. Gohary O.M., Kassas R.S. Stability studies of aspirin-magaldrate double layer tablets. Pharmaceutica Acta Helvetiae. 2000;74(4):351-60. DOI:10.1016/S0031-6865(99)00045-X.

25. Campanella L., Micieli V., Tomassetti M., et al. Kinetic investigation and predictive model for the isothermal degradation time in two commercial acetylsalicylic acid-based pharmaceutical tablet formulations. Thermochimica Acta. 2011;526(1-2):151-6. DOI:10.1016/j.tca.2011.09.008.

26. Mylrea M., Robertson S., Haywood A., et al. Stability of dispersible aspirin tablets repacked into dosette boxes. Journal of Pharmacy Practice and Research. 2012;42(3):204-7. DOI:10.1002/j.2055-2335.2012.tb00171.x.

27. Patrono C., Garca Rodnguez L., Landolfi R., et al. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med. 2005;353(22):2373-83. DOI: 10.1056/NEJMra052717.


For citation:


Lomakin N.V., Buryachkovskaya L.I., Zolin D.A., Kazey V.I. A Prospective, Initiative, Single-Center Open Post-Registration Comparative Study of Laboratory Efficacy of Various Forms of Acetylsalicylic Acid in a Cardioprotective Dose with Different Composition of Excipients: Results of the SFAIROS Study. Rational Pharmacotherapy in Cardiology. 2020;16(3):348-355. (In Russ.) https://doi.org/10.20996/1819-6446-2020-06-06

Views: 187


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)